PFIZER’S CENTERS FOR THERAPEUTIC INNOVATION (CTI)

REQUEST FOR TRANSLATIONAL PROPOSALS: BIOTHERAPEUTIC TARGETS

Proposal Deadline: Must be emailed to biotech@einstein.yu.edu NO LATER than FRIDAY, June 5, 2015

CTI is an innovative Pfizer program that partners with leading academic medical centers and patient foundations nationwide to speed the translation of novel targets into potential therapeutics. CTI seeks to identify and partner novel targets with the goal of identifying new compounds and accelerate drug development from validated target to proof-of-mechanism in humans. A partnership with CTI may include collaborative use of Pfizer’s proprietary antibody drug delivery technologies, broad publishing rights and financial awards in the form of milestone and royalty payments for successful programs.

Large Molecule Modalities in Scope
› Antibodies, Proteins, Peptides

Therapeutic Areas of Interest:
› Inflammation
› Autoimmunity
› Tissue remodeling
› Oncology
› Cancer Immunology
› Rare or genetic diseases
› Cardiovascular and metabolic diseases
› Neuroscience

What We Look For
› Strong Project Rationale: Demonstrated association between target biology and disease mechanism
› Ability to Address Unmet Medical Needs
› Validated Therapeutic Drug Target: Strong link from targeted pathway to disease, and a tractable target relative to proposed drug modalities
› Feasibility: Plan to candidate development and translation into the clinic
› Clinical Differentiation: Opportunity for underpinning therapeutic strategy via patient stratification, molecular signatures, genetic associations, biomarkers

Further guidance is attached below (for those receiving e-flyers) or is available from your Tech Transfer Office

Proposal Submission Process:
› The Pre-Proposal is a brief NON-CONFIDENTIAL 2-3 page overview of the mechanism and proposed research plan to demonstrate proof of mechanism (template attached below for those receiving e-flyers, or obtained from your Tech Transfer Office)
› Submit the Pre-Proposal to your Tech Transfer Office (contact below) by June 12, 2015 who will then submit for review by the Joint Steering Committee via the CTI portal

All researchers, clinicians and post-docs whose work meets these criteria are invited to apply. For more information, please contact Janis Paradiso at the Offices of Biotechnology and Business Development janis.paradiso@einstein.yu.edu
CTI looks for projects that have:

- **Strong Project Rationale**
  - Demonstrated association between target biology, pathway and disease mechanism
  - Target validation as demonstrated by genetic or pharmacologic evidence

- **Therapeutic Area Opportunity**
  - Unmet medical needs, opportunity for novel therapeutic mechanism or modality in in-scope therapeutic areas

- **Therapeutic Drug Target**
  - Novel target, novel therapeutic strategy or new insight into target patient population
  - Defined target
  - Demonstrated cause/effect relationship to disease mechanism
  - Understanding of desired pharmacology
  - Tractability of target relative to drug modalities (e.g., monoclonal antibodies, peptides, proteins or, where applicable, small molecules), available reagents, assays and technologies

- **Project Feasibility**
  - Clear path to candidate development (biochemical/cell-free/cellular assays, disease models, preclinical testing, etc.)
  - Clear path to FIH clinical trial (approach for proof-of-mechanism in humans, accessible patient population, timeframe, safety issues, etc.)

- **Ability to Translate Basic Biological Research into the Clinic**
  - From molecular mechanism to therapeutic opportunity
  - Therapeutic strategies may include personalized medicine, patient stratification, molecular signatures, genetic associations, biomarkers

Platform technologies and exploratory research (e.g., target discovery, development of animal models, cell line models, indication expansion or mechanism of action for existing drugs) are generally out of scope for CTI. In-licensing opportunities are also generally out-of-scope although CTI may consider proposals for pre-existing drug candidates based upon discussions with the PI and TTD.